Better PROs With Niraparib Maintenance in Ovarian Cancer

(MedPage Today) -- Quality of life in women with ovarian cancer was not reduced despite the added toxicity of niraparib (Zejula) maintenance in the PRIMA trial, according to a presentation at the 2020 European Society for Medical Oncology (ESMO...